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Available online 6 August 2019Background:We recently demonstrated that maternal dietary supplementation with ﬁsh oil-derived n-3 long-
chain polyunsaturated fatty acids (n-3 LCPUFAs) during pregnancy reduces the risk of asthma in the offspring
but the mechanisms involved are unknown.
Methods: Here we investigated potential metabolic mechanisms using untargeted liquid chromatography-mass
spectrometry-basedmetabolomics on 577 plasma samples collected at age 6months in the offspring of mothers
participating in the n-3 LCPUFA randomized controlled trial. First, associations between the n-3 LCPUFA supple-
mentation groups and child metabolite levels were investigated using univariate regression models and data-
driven partial least square discriminant analyses (PLS-DA). Second, we analyzed the association between the
n-3 LCPUFAmetabolomic proﬁle and asthma development using Cox-regression. Third, we conductedmediation
analyses to investigate whether the protective effect of n-3 LCPUFA on asthma was mediated via the metabo-
lome.
Findings: The univariate analyses and the PLS-DA showed that maternal ﬁsh oil supplementation affected the
child's metabolome, especially with lower levels of the n-6 LCPUFA pathway-related metabolites and saturated
and monounsaturated long-chain fatty acids-containing compounds, lower levels of metabolites of the trypto-
phan pathway, and higher levels of metabolites in the tyrosine and glutamic acid pathway. This ﬁsh oil-related
metabolic proﬁle at age 6 months was signiﬁcantly associated with a reduced risk of asthma by age 5 and the
metabolic proﬁle explained 24% of the observed asthma-protective effect in the mediation analysis.
Interpretation: Several of the observed pathwaysmay be involved in the asthma-protective effect ofmaternal n-3
LCPUFA supplementation and act as mediators between the intervention and disease development.
Funding: COPSAC is funded by private and public research funds all listed on www.copsac.com.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Metabolomics
Fish oil
Childhood asthma1. Introduction
Asthma is the most common chronic disease in childhood and has
doubled in prevalence over the last decades in Westernized countries
[1]. This rapid increase in disease prevalence is believed to be caused
by changes in lifestyle and human diet, particularly, an increased intaketudies on Asthma in Childhood,
n, Ledreborg Alle 34, DK-2820
bisgaard@copsac.com
. This is an open access article underof n-6 long-chain polyunsaturated fatty acids (n-6 LCPUFAs) and a
decreased intake of n-3 LCPUFAs amongpregnantmothers, has been as-
sociated with an increased risk of asthma in the offspring [2]. The main
dietary source of n-3 LCPUFA comes from ﬁsh and other seafood, espe-
cially from cold-water fatty ﬁsh such as salmon and mackerel, and/or
from dietary supplements such as dietary ﬁsh oil capsules. Due to
those observations, we conducted a double-blind randomized con-
trolled trial (DB-RCT) of supplementationwithﬁshoil duringpregnancy
in the Copenhagen Prospective Studies on Asthma in Childhood 2010
(COPSAC2010) mother-child cohort. This resulted in a 31% reduced risk
of asthma in the offspring during their ﬁrst 5 years of life [3]. Thus, n-
3 LCPUFA supplementation during pregnancy holds promise for the pri-
mary prevention of childhood asthma, but the underlying mechanisms
of the asthma-protective effect of LCPUFA remain to be elucidated.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The global increase in childhood asthma prevalence has been ob-
served in parallel with an increasing dietary intake of n-6 polyun-
saturated fatty acids (PUFA) from e.g. vegetable oils and
decreasing intake of n-3 LCPUFAs found in fish, suggesting amod-
ifiable link between n-3 LCPUFA deprived diet during pregnancy
and offspring asthma risk. Recently, we proved that hypothesis
in a double-blind, randomized controlled trial of supplementation
with fish oil-derived n-3 LCPUFAor placebo during third pregnancy
trimester, showing 31% reduced risk of asthma in the offspring by
age 5. However, the underlying mechanism behind the supple-
mentation effect is unknown.
Added value of this study
In this studyweusedglobal, untargetedmetabolomics profiles from
plasma samples collected at age 6 months in the children born to
mothers participating in the n-3 LCPUFA trial to investigate meta-
bolic perturbations related to the prenatal n-3 LCPUFA supplemen-
tation and whether those perturbations explained some of the
underlying biology of the asthma-protective effect. We observed
differences in several metabolic pathways, which have previously
been related to asthma such as n-6 LCPUFA pathway-related me-
tabolites and tryptophan metabolites as well as metabolites in the
tyrosine and glutamic acid pathway. Further, we showed that
these n-3 LCPUFA relatedmetabolic perturbationswere associated
with a reduced risk of asthma by age 5 and significantly mediated
one fourth of the asthma-protective effect observed in the trial.
Implications of all the available evidence
These findings provide novel insight into themetabolic effects of di-
etary n-3 LCPUFA supplementation and the pathogenesis of child-
hood asthma. Further, this study is an example of translational
research,wheremechanisms of a clinically import finding from a di-
etary, randomized controlled trial are explored usingmetabolomics.
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tabolome, which is the complete set of small-molecule metabolites in
a biological sample. By generating a complete metabolomic proﬁle of a
speciﬁc bioﬂuid, such as plasma, from a cohort of individuals [4], meta-
bolomics can be applied to disentangle molecular mechanisms of
complex diseases such as asthma or metabolic consequences of envi-
ronmental exposures, such as diet. Hitherto, metabolomic proﬁling
studies have shown promising results for identifying the underlying
mechanisms of asthma [5]. Furthermore, metabolomics enables study-
ing the long-term downstream metabolic effects in the child of micro-
nutrient and macronutrient supplementation during pregnancy [6],
such as n-3 LCPUFAs.
The objective of this study was to conduct plasma metabolomic
proﬁling using untargeted liquid chromatography-mass spectrometry
(LC-MS) technique on blood sampled at age 6months in the COPSAC2010
cohort to explore potential biochemicalmechanisms behind the asthma-
protective effect of n-3 LCPUFA supplementation during pregnancy.
2. Methods
2.1. Study population
The Copenhagen Prospective Studies on Asthma in Childhood2010
(COPSAC2010) cohort is a population-based mother-child cohort in
which 700 pregnant women were recruited between 22 and 26 weeksof gestation and their children subsequently followed prospectively
during their ﬁrst ﬁve years of life at 12 scheduled clinical visits. All the
visits were conducted at the COPSAC research center, where trained pe-
diatricians examined the children and collected exposure information
at age 1week, 1, 3, 6, 12, 18, 24, 30, and 36months after birth, and yearly
thereafter. In addition, whenever the children experienced lung, allergy
or skin-related symptoms the families attended acute care visits at the
research unit, where the COPSAC pediatricians diagnosed and treated
asthma, allergy, and eczema in accordancewith predeﬁned validated al-
gorithms [7]. Furthermore, the parents ﬁlled daily diary cards prospec-
tively from birth recording signiﬁcant troublesome lung symptoms,
including cough, wheeze, and dyspnea, anti-asthmatic treatment, skin
symptoms and treatment, and infections.
2.2. n-3 LCPUFA trial
The pregnant women were enrolled in a double-blind, randomized
controlled trial (DB-RCT) [3]. At enrollment during pregnancy week
22–26, the women were randomly assigned in a 1:1 ratio to receive
2.4 g per day of n− 3 long-chain polyunsaturated fatty acids (LCPUFAs)
in triacylglycerol form from ﬁsh oil capsules containing 55%
eicosapentaenoic acid (20:5n–3, EPA) and 37% docosahexaenoic acid
(22:6n–3, DHA (Incromega TG33/22, Croda, Health Care) or placebo in
the form of lookalike olive oil capsules, containing 72% n–9 oleic acid
and 12% n− 6 linoleic acid (Pharma-Tech A/S). The women continued
taking the daily supplement until 1 week after delivery, where they vis-
ited the research unit with their child. A subgroup of the pregnant
women (n = 623) also participated in another DB-RCT with a nested
2 × 2 factorial design inwhich theywere assigned to 2400 IU of vitamin
D per day or placebo from pregnancy week 22–26 till 1 week postpar-
tum on top of the recommended pregnancy supplement of 400 IU/d;
i.e. the women received 2800 vs. 400 IU/d of vitamin D, which did not
signiﬁcantly affect the offspring's risk of developing asthma [3].
2.3. Ethics statement
The trial was approved by The National Committee on Health
Research Ethics (H-B-2008-093) and theDanishData Protection Agency
(2015-41-3696). Both parents gave oral and written informed consent
before enrollment.
2.4. Asthma diagnosis
Asthma or persistent wheeze was the primary end point of the DB-
RCT of n-3 LCPUFA supplementation during pregnancy and was solely
diagnosed by the COPSAC pediatricians based on a quantitative vali-
dated symptom algorithm [8,9], including all of the following four
criteria: (1) veriﬁed diary recordings of at least ﬁve episodes of trouble-
some lung symptomswithin sixmonths, each lasting at least three con-
secutive days; (2) symptoms typical of asthma, including exercise-
induced symptoms, prolonged nocturnal cough, and/or persistent
cough outside of common colds; (3) need for intermittent rescue use
of inhaled β2-agonist; and (4) response to a three-month course of in-
haled corticosteroids and relapse upon ending treatment [8].
2.5. Covariates
2.5.1. Breastfeeding
Information about the duration of exclusive and total breastfeeding
duration was obtained during the scheduled visits to the COPSAC clinic
and recorded online in a dedicated database.
2.5.2. FADS genotyping
Maternal and child variation in the gene encoding fatty acid
desaturase (FADS2) was assessed by genotyping the single-nucleotide
polymorphism (SNP) rs1535. Genotyping was performed using the
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Applied Biotechnology AS center, Aarhus, Denmark. Genotypes were
called with Illumina Genome Studio software and rs1535 was geno-
typed on this array. We excluded individuals with individual genotyp-
ing call rate b 0.95, gender mismatch, genetic duplicates or outlying
heterozygosity N 0.27 and b0.037. Furthermore, maternal genotyping
was solely done in mothers of European descent as there are very few
non-Caucasian mothers in the cohort.
2.5.3. Blood sample collection and storage
A blood sample was collected from the child when visiting the re-
search clinic at age 6 months. The blood sample was collected in an
EDTA tube and left at room temperature for 30 min and thereafter
spun down for 10 min at 4000 rpm. The supernatant was collected
and stored at−80 °C until further analysis.
2.6. Liquid Chromatography-Mass Spectrometry (LC-MS) metabolomics
analysis
2.6.1. Sample preparation
The untargeted metabolomic analysis of the plasma samples was
carried out by Metabolon, Inc. (NC, USA). Brieﬂy, the sample prepara-
tion was done using the automated system MicroLab STAR® system
fromHamilton Company. Prior to extraction, the samples were fortiﬁed
with recovery standards for quality control (QC) purposes. Methanol
was used to extract the metabolites and precipitate the proteins during
vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed by
centrifugation. The resulting extract was divided into four aliquots to be
subsequently analyzed by LC-MS/MS comprising of four platforms.
Samples were placed on a TurboVap® (Zymark) to remove the organic
solvent and stored overnight under nitrogen before preparation for LC-
MS/MS analysis.
2.6.2. LC-MS/MS analysis
All the four platforms utilized an ACQUITY Ultra-Performance Liquid
Chromatography (UPLC) (Waters, Milford, USA) and a Q Exactive™Hy-
brid Quadrupole-Orbitrap™mass spectrometer interfaced with heated
electrospray ionization (HESI-II) source (ThermoFisher Scientiﬁc, Wal-
tham, Massachusetts, USA). The sample extracts were reconstituted in
solvents compatible to each of the four LC-MS methods: two separated
reverse phase UPLC-ESI(+)MS/MS methods optimized for hydrophilic
and hydrophobic compounds; one reverse phase UPLC-(−)MS/MS
using basic optimized conditions; and one HILIC/UPLC-(−)MS/MS.
The MS analysis alternated between full scan MS and data-dependent
MSn scans using dynamic exclusion. The scan range for both ionization
modes was 70–1000m/z.
2.6.3. Data collection and quality control
The rawdatawas extracted, peak identiﬁed, andQCprocessed. Sam-
ples were semi-quantiﬁed using area-under-the-curve. Peak identiﬁca-
tion was done by automated comparison of the ion feature in the
experimental spectrum to the ions present in the library spectrum of
authenticated standards or recurrent unknown entities. The identiﬁca-
tion was based on three matching criteria: narrow retention time/
index (RI) range, mass accuracy (±10 ppm) and MS/MS spectra. The
identiﬁcation level reported in this paper follows the criteria described
by Summer LW et al. [10]. Compounds labelled with “*” have identiﬁca-
tion level 2, compounds labelled with “**” have level 3 (since no stan-
dards or matching spectra are available). Compounds named with
“X-#” are unknown and therefore have level 4. If no label is applied,
the identiﬁcation level is 1.
Throughout the analyses of the batches, different kinds of samples
were analyzed for instrument performance monitoring: a well-
characterized human plasma as a technical replicate, extracted water
samples as process blanks, and a mixture of QC standards (not interfer-
ing with the measurement of endogenous compounds) spiked in everyanalyzed sample prior to injection. The instrument variability was de-
termined by calculating the median relative standard deviation (RSD)
for the QC standards spiked in. It ranged around 7%. The total process
variability was determined by calculating themedian RSD for all endog-
enous metabolites (i.e., non-instrument standards) present in the tech-
nical replicates. It resulted to be within 10%.
2.7. Statistical analysis
2.7.1. Data preprocessing
Each compound was corrected in run-day blocks by registering the
medians to equal one (1.00) andnormalizing each variable, accordingly.
This data normalization procedure that was done for all the dataset
from the four platforms was performed to compensate for the inter-
day variation. The ﬁnal set of variables from all the four platforms was
imported into Matlab (Version 9.3, the Mathworks, Inc., MA, USA) and
RStudio (Version 1.1, RStudio, Inc) for the statistical analysis.
In order to remove spurious information prior to data analysis, sam-
ples having ≥30% of missing values as well as metabolites containing
≥70% of missing values were discarded. Furthermore, since the aim of
our analysis was to investigate the effect of the n-3 LCPUFA supplemen-
tation during pregnancy on the child metabolome at 6 months of age,
variables not present in at least 70% of the samples in either the n-3
LCPUFA or placebo group were removed [11]. Finally, missing values
were imputed with zeros.
2.7.2. Univariate linear regression analysis
Firstly, linear regression analysis was performed to compare the rel-
ative concentrations of the imported set of metabolites (features) in the
n-3 LCPUFA supplementation vs. placebo group. Signiﬁcant features
were reported at a nominal signiﬁcance level in this exploratory analy-
sis (p-values ≤ .05 from “Wald test”).
Linear regression analysis was also used to correlate solely
breastfeeding duration with selected metabolite levels. The intercept
of such model also allowed to estimate the levels of the compounds in-
dependent by the breastfeeding. Thereafter, stratifying the analysis by
the n-3 LCPUFA intervention allowed us to estimate the difference in
modelled metabolite levels at birth vs. at 6 months (time of sampling)
by the slope. In order to test if those differences were signiﬁcant, we
used simultaneous tests for general linear hypotheses from the
“multcomp” R package.
Inﬂuence of maternal and child FADS2 genotype were also investi-
gated using linear regressionmodels. Genotypewas associatedwith se-
lected metabolites level in the n-6 pathway stratiﬁed by treatment and
accounting for each other genotype and exclusively breastfeeding dura-
tion. The association is reported per copy of the minor allele G in terms
of beta-estimate, standard error (SE) and signiﬁcance (p-value from
“Wald test”).
2.7.3. Multivariate partial least squares discriminant analysis (PLS-DA)
After the univariate analysis, PLS-DA was employed to classify the
differences between metabolites in the n-3 LC-PUFA supplement
group compared to placebo. Initially, the dataset was imported into
the PLS_Toolbox (Version 8.61, Eigenvector Research, Inc., MA, USA)
and auto-scaled prior to analysis. The PLS-DA model validation was
done by iterating 100×, using a 10-fold cross-validation model in the
training set in which the number of PLS-DA components was chosen
based on the lowest misclassiﬁcation error. During each iteration, the
rank of each feature was recorded based on its selectivity ratio (SR)
and the model was validated based on misclassiﬁcation error on a ran-
dom test set selected up-front and using 20% of the original dataset.
The product of the ranks was used to sort the variables ascending
(low rank, high importance) and successively to select themost impor-
tant ones based on the lowestmisclassiﬁcation error on the random test
set (20% of the total samples) whenmodels were built including 10 var-
iables at the time and startingwith 11 initial features [12]. Furthermore,
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siﬁcation performance of the ﬁnal PLS-DAmodel with the selected var-
iables, where the p-values are from a randomization t-test.
2.7.4. Rotated model
The PLSDA model estimates the linear combination of the original
matrix (X (n,p)) that most optimally relates to the intervention
(f (n,1)) by ﬁnding a so called score matrix (T= XW (n,k)). This score
matrix by deﬁnition captures the structure in the metabolomics data
table (X) that has maximum covariance with the intervention. How-
ever, as the estimation do not utilize information of the clinical outcome
(asthma at 6y of age: o (n,1)), the metabolomics intervention ﬁnger-
print related to asthma will be distributed across all k components. In
order to make a more parsimonious model, that in the ﬁrst component
(T1) reﬂects the invention ﬁngerprint related to outcome while leaving
the part that is only related to intervention, but not outcome in the re-
maining components (T2,…, Tk) the score matrix is rotated towards
the outcome using orthogonal procrustes rotation [13].
2.7.5. Enrichment analysis
One-sided Fisher's exact test was performed to investigate for any
pathway enrichment within the selected metabolites. For each path-
way, a contingency table (2 × 2) was made, see Table S1 in the Supple-
mentary Material for further details. Enrichment is deﬁned for
signiﬁcantly (p-value b .05) higher odds for inclusion of a metabolite
for the i'the pathway compared to all other pathways.
2.7.6. Cox-regression and mediation analysis
Cox regression analysis using the “survival” R package was
employed to assess the correlation between the components of the ro-
tated PLS-DA model (which were z-scored), that describes the differ-
ence between n-3 LCPUFA and placebo, and the risk of developing
asthma during the ﬁrst 5 years of life. Reported p-values are from
Wald test. A Kaplan-Meier curve was used to representing the associa-
tion between the PLS-DA component scores divided into tertiles and
risk of developing asthma.
To assess the mediation effect between the components of the ro-
tated PLS-DA model and the development of asthma during the ﬁrst
5 years of life, the R package “mediation” was used with 95% CIs based
on quasi-Bayesian approximation using 10,000 Monte-Carlo draws.
The mediation analysis was built in the following way:
ﬁrstly, a linear model was built associating the rsLV1 and the n-3
LCPUFA supplementation (Model 1), followed by a binomial model as-
sociating the asthma diagnosed till age 5 years (n= 116) and the n-3
LCPUFA supplementation plus the rsLV1 (Model 2). Afterwards, a
thirdmodel was built combining these twomodels together and impos-
ing rsLV1 asmediating factor between the asthma development and the
n-3 LCPUFA supplementation (Model 3).
Model 1 Intervention vs rLV1ð Þ : lm rsLv1  interventionð Þ ð1Þ
Model 2 asthmað Þ : glm asthma  interventionþ rLV1ð Þ ð2Þ
Model 3 Model 1þModel 2ð Þ
: mediation Model 1;Model 2;mediator ¼ }rLV1}ð Þ
2.8. Data availability
De-identiﬁed metabolomics data is deposited in the publicly avail-
able data repository, “Metabolomics Workbench” under Study ID:
ST001212, and it is also available with this article (Supplementary
material 1).3. Results
3.1. Baseline characteristics of the study
The COPSAC2010 mother-child cohort of 736 pregnant women and
their 695 children has previously been described in detail [7]. Blood
samples were collected for metabolomic proﬁling from 602 children at
6 months up to 2 years of age. Of those, only samples from children
aged 4–8 months were included in the analysis as their metabolomic
proﬁles were similar in a principal component analysis (PCA) compared
to samples collected from children at older ages (see Supplementary
Material). These metabolomic proﬁles contained 1138 unique metabo-
lites that were identiﬁed using mass to charge ratio, retention time,
and a library of metabolites (see Supplementary Material). Following
the subsequent quality control steps removing sampleswith ≥30%miss-
ing values aswell as featureswith ≥70%missing values resulted in aﬁnal
dataset including samples from 577 children (51% boys) with 831 me-
tabolites. The composition of the remaining metabolites after these
quality control procedures is shown in Figure SF3 (in the Supplemen-
tary Material), where the metabolites are grouped based on sub path-
way (Panel a) and the most abundant pathways with N10 compounds,
which are lipids and amino acids (Panel b).
A total of 51 (8.9%) children were exclusively breastfed for less than
a week from birth, 553 (96.2%) terminated the exclusive breastfeeding
before the time of metabolomic sampling, whereas 22 (3.8%) were
still exclusively breastfed at the time of metabolomic sampling, and
breastfeeding status was unknown for 2 children. An overview of the
baseline characteristics is presented in Table S2 (see Supplementary
Material).
3.2. n-3 LCPUFA supplementation during pregnancy and the child
metabolome
In order to investigate differences in the plasma metabolomic pro-
ﬁles between children whose mothers received n-3 LCPUFA supple-
mentation or placebo, we used univariate linear regression models for
eachmetabolite followed by a partial least squares discriminant analysis
(PLS-DA) model.
3.3. Univariate linear regression analysis
Among the 831 features investigated, 42 showed a nominally signif-
icant difference at a p= .05 level between the n-3 LCPUFA supplemen-
tation and the placebo group. The volcano plot in Figure SF5 [in the
Supplementary Material] summarizes the results showing the effect es-
timates vs. p-values. The results are further detailed in the heatmap in
Figure SF6 [in the Supplementary Material] that shows the signiﬁcant
metabolites and their associated sub-pathways. As shown in
Figure SF6, the lipids and the amino acid pathways are the onesmost af-
fected by the n-3 LCPUFA supplementation with higher hydroxy-3-
carboxy-4-methyl-5-propyl-2-furanpropanoic acid (hydroxy-CMPF)
and lower n-6 docosapentaenoic acid (DPA, 22:5n-6) being the two
most perturbed compounds. Among the signiﬁcant metabolites, 7
have unknown identities, see Table S3 [in the Supplementary Material]
andwill not bementioned or discussed further. Due to natural collinear-
ity between metabolites and the scope of the univariate models being
merely exploratory supportive analyses, we did not apply FDR correc-
tion. However, the univariate analyses results should be interpreted
with caution.
3.4. Multivariate PLS-DA and pathway enrichment analysis
Based on all themetabolome features for classifying children accord-
ing to pregnancy supplementation, the best PLS-DAmodel comprised 5
components and 121 metabolites. This model had a misclassiﬁcation
error of 0.29, an AUC of 0.77 and a permutation test p-value = .005
403D. Rago et al. / EBioMedicine 46 (2019) 399–410for discriminating between n-3 LCPUFA supplementation and placebo.
The score plot of the ﬁrst two components (LV1 and LV2, explaining
10.99% and 9.39% of the variation, respectively) is shown in Fig. 1
Panel A, illustrating that children in the n-3 LCPUFA supplementation
group have higher scores in both components compared to children in
the placebo group. The corresponding loading plot is shown in Fig. 1
Panel a, where the signiﬁcant compounds from the univariate linear re-
gression analysis are labelled.
Most of the observed association of the pregnancy n-3 LCPUFA sup-
plementation on the child metabolome is related to lower levels of
lipid-related compounds containing n-6 unsaturated, monounsaturated
or saturated long-chain fatty acids (FAs). Especially, arachidonic
acid (AA, 20:4n6) and its esteriﬁed forms (plasmalogens,
lysophosphatidylcholines, phosphatidylcholines, phosphatidylinositols,
diacylglycerols), dihomo-linolenic acid (20:3n-6) and n-6
docosapentaenoic acid (n6-DPA, 22:5n-6) were lower in the n-3
LCPUFA supplementation group. This is illustrated in Table 1,which pro-
vides an overview of the metabolites contributing the most in the ﬁrst
two PLS-DA components grouped by subpathway, including the fold
change. For the remaining set of metabolites (N= 69), see Table S5 in
the Supplementary Material.
The n-3 LCPUFA supplementation also resulted in a decrease in
xanthurenic acid in the tryptophan pathway and an increase in the
glutamic acid and tyrosine pathway-related compounds. We also ob-
served association with the carnitine metabolism pathway with in-
crease of carnitines and decrease of acylcarnitine-related compounds.
Finally, a decrease of ceramides and sphingolipids containing 18:0 and
22:0 FAs and an increase in hydroxy-CMPF, a metabolite associated
with ﬁsh or ﬁsh oil intake,was prevalent in the children,whosemothers
received n-3 LCPUFA (Table 1).Fig. 1. PLS-DA analysis. a) Loadings plot of the ﬁrst two components of the PLS-DA analysis. The
in common with the linear regression analysis. b) Scores plot of the ﬁrst two components of
placebo).Among the 121 metabolites in the ﬁnal PLS-DA model, 29 com-
pounds are of unknown identity and are reported in Table S5 in the
Supplementary Material. Performing an enrichment analysis based on
sub-pathways on the remaining92metabolites, we observed signiﬁcant
enrichment in the tyrosine pathway, as shown in Fig. 2.
3.5. Maternal and child FADS2 genotype and LCPUFA levels at age 6 month
It has been shown that levels of n-3 LCPUFAs are related to the activ-
ity of the fatty acid desaturase (FADS) enzymes (Δ5-desaturase andΔ6-
desaturase), which are involved in the formation of the LCPUFAs from
essential FAs [14]. Those enzymes are encoded by the FADS1 and
FADS2 genes located on chromosome 11 [15,16].
In this DB-RCT of n-3 LCPUFA supplementation during pregnancy,
we showed that the mother's levels of eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) at enrollment at pregnancy week 24
were associated with the FADS2 genotype (rs1535) with lower levels
in mothers carrying the minor allele (G) [3]. Therefore, we tested
whether maternal and/or child FADS2 genotype inﬂuenced the levels
of the FAs and esteriﬁed forms in the n-6 pathway, that we found
were signiﬁcantly associated with the n-3 LCPUFA supplementation in
our analysis. The analyses were stratiﬁed by n-3 LCPUFA supplementa-
tion or placebo using both maternal and child FADS2 genotype in
models adjusted for each other. The results are presented in Table 2
showing that maternal FADS2 genotype was signiﬁcantly and nega-
tively associated with the levels of all the n-6 pathway-related metabo-
lites in the placebo strata with lower levels per number of the G minor
allele,whereas no associationswere observed formaternal FADS2 geno-
type in the n-3 LCPUFA group. No associations were observed between
child FADS2 genotype and the n-6 pathway-related metabolites in ei-
ther the n-3 LCPUFA or the placebo strata.compounds are colored based on their sub-pathway. The labelled compounds are the ones
the PLS-DA analysis. The samples are colored based on the intervention (n-3 LCPUFA or
Table 1
Mainmetabolites inﬂuencing the PLS-DAmodel, reported in terms of effect sizewhen stratifying by the intervention. A negative effect size represents the effect towards the placebo group.
Compound, Sub-pathway Treatment Effect size Metabolism
1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)*, Plasmalogen Placebo n3/n6 Fatty Acid Metabolism
n3 LCPUFA −0.2
1-(1-Enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)*, Plasmalogen Placebo
n3 LCPUFA −0.1
1-Arachidonoyl-GPC (20:4n6)*, Lysophospholipid Placebo
n3 LCPUFA −0.2
1-Arachidonoyl-GPE (20:4n6)*, Lysophospholipid Placebo
n3 LCPUFA −0.2
1-Palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6), Phosphatidylcholine (PC) Placebo
n3 LCPUFA −0.2
1-Stearoyl-2-arachidonoyl-GPC (18:0/20:4), Phosphatidylcholine (PC) Placebo
n3 LCPUFA −0.2
1-Stearoyl-2-arachidonoyl-GPI (18:0/20:4), Phosphatidylinositol (PI) Placebo
n3 LCPUFA −0.2
Dihomo-linolenate (20:3n3 or n6), Polyunsaturated Fatty Acid (n3 and n6) Placebo
n3 LCPUFA −0.1
Docosapentaenoate (n6 DPA; 22:5n6), Polyunsaturated Fatty Acid (n3 and n6) Placebo
n3 LCPUFA −0.3
Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2]*, Diacylglycerol Placebo
n3 LCPUFA −0.1
Stearidonate (18:4n3), Polyunsaturated Fatty Acid (n3 and n6) Placebo
n3 LCPUFA −0.2
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1]*, Diacylglycerol Placebo
n3 LCPUFA −0.2
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [2]*, Diacylglycerol Placebo
n3 LCPUFA −0.2
3-Hydroxybutyrate (BHBA), Ketone Bodies Placebo Lipid oxidation
n3 LCPUFA −0.1
Carnitine, Carnitine Metabolism Placebo
n3 LCPUFA 0.1
Decanoylcarnitine (C10), Fatty Acid Metabolism(Acyl Carnitine) Placebo
n3 LCPUFA −0.2
Myristoleoylcarnitine (C14:1)*, Fatty Acid Metabolism(Acyl Carnitine) Placebo
n3 LCPUFA −0.2
Octanoylcarnitine (C8), Fatty Acid Metabolism(Acyl Carnitine) Placebo
n3 LCPUFA −0.2
Propionylcarnitine (C3), Fatty Acid Metabolism (also BCAA Metabolism) Placebo
n3 LCPUFA 0.2
3-(4-Hydroxyphenyl)lactate, Tyrosine Metabolism Placebo Tyrosine Metabolism
n3 LCPUFA 0.1
3-Methoxytyramine sulfate, Tyrosine Metabolism Placebo
n3 LCPUFA 0.1
4-Hydroxyphenylpyruvate, Tyrosine Metabolism Placebo
n3 LCPUFA 0.2
Gentisate, Tyrosine Metabolism Placebo
n3 LCPUFA 0.2
Tyrosine, Tyrosine Metabolism Placebo
n3 LCPUFA 0.1
Vanillylmandelate (VMA), Tyrosine Metabolism Placebo
n3 LCPUFA 0.1
4-Hydroxyglutamate, Glutamate Metabolism Placebo Glutamate Metabolism
n3 LCPUFA 0.3
Glutamate, Glutamate Metabolism Placebo
n3 LCPUFA 0.2
3-Indoxyl sulfate, Tryptophan Metabolism Placebo Tryptophan Metabolism
n3 LCPUFA 0.1
Xanthurenate, Tryptophan Metabolism Placebo
n3 LCPUFA −0.2
3-Carboxy-4-methyl-5-pentyl-2-furanpropionate (3-Cmpfp)**, Fatty Acid, Dicarboxylate Placebo Furan Fatty Acid Metabolism
n3 LCPUFA −0.2
Hydroxy-CMPF*, Fatty Acid, Dicarboxylate Placebo
n3 LCPUFA 0.8
N-Behenoyl-sphingadienine (d18:2/22:0)*, Sphingolipid Metabolism Placebo Other
n3 LCPUFA −0.1
Behenoyl sphingomyelin (d18:1/22:0)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Sphingomyelin (d17:2/16:0, d18:2/15:0)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Sphingomyelin (d18:1/19:0, d19:1/18:0)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Sphingomyelin (d18:1/24:1, d18:2/24:0)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Sphingomyelin (d18:2/21:0, d16:2/23:0)*, Sphingolipid Metabolism Placebo
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Table 1 (continued)
Compound, Sub-pathway Treatment Effect size Metabolism
n3 LCPUFA −0.1
Eicosanodioate (C20-DC), Fatty Acid, Dicarboxylate Placebo
n3 LCPUFA 0.1
Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Sphingomyelin (d18:2/23:1)*, Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
Stearoyl sphingomyelin (d18:1/18:0), Sphingolipid Metabolism Placebo
n3 LCPUFA −0.1
1-(1-Enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)*, Plasmalogen Placebo
n3 LCPUFA 0.1
Ceramide (d18:1/17:0, d17:1/18:0)*, Ceramides Placebo
n3 LCPUFA −0.2
Eicosenoate (20:1), Long Chain Fatty Acid Placebo
n3 LCPUFA −0.2
Erucate (22:1n9), Long Chain Fatty Acid Placebo
n3 LCPUFA −0.2
Glycerophosphoglycerol, Glycerolipid Metabolism Placebo
n3 LCPUFA 0.1
Glycosyl ceramide (d18:1/23:1, d17:1/24:1)*, Ceramides Placebo
n3 LCPUFA −0.3
Glycosyl ceramide (d18:2/24:1, d18:1/24:2)*, Ceramides Placebo
n3 LCPUFA −0.2
Glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)*, Ceramides Placebo
n3 LCPUFA −0.2
Myristoleate (14:1n5), Long Chain Fatty Acid Placebo
n3 LCPUFA −0.1
Nonadecanoate (19:0), Long Chain Fatty Acid Placebo
n3 LCPUFA −0.2
405D. Rago et al. / EBioMedicine 46 (2019) 399–4103.6. Breastfeeding and child metabolite levels at age 6 months
Many metabolites can be transferred from mothers to children via
the breastmilk and breastfeeding status may therefore inﬂuence the
child metabolome. To disentangle this, we investigated the association
between duration of exclusively breastfeeding and levels of each of the
main metabolites driving the PLS-DA model. We used the exclusively
breastfeeding duration rather than the total breastfeeding duration,
sincewe consider this a better estimate of breastfeedingexposure. How-
ever, in order to exclude possible differences due to any breastfeeding at
the time of sampling, we repeated the analysis using the difference in
days between the sampling date and the end of any breastfeeding. No
substantial differences were observed. The results from these correla-
tionmodels are depicted in Figure SF7 (in the SupplementaryMaterial),
showing that the levels of all the lipid related compounds (long chain
fatty acids, sphingolipids, lysophospholipids, ceramides, carnitines,
etc) are positively associated with exclusive breastfeeding duration in
both the n-3 LCPUFA and placebo strata; i.e. increasing levels with in-
creasingbreastfeedingduration independentof supplementation status.
A fewof themetabolites showed inverse associationswithbreastfeeding
such as xanthurenic acid, 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE
(P-18:0/20:4) and eicosanodioic acid (C20-DC).
To further explore the role of breastfeeding, we used the intercept
from themetabolite vs. breastfeeding lengthmodels to estimatemetabo-
lite levels for a breastfeeding length of 0 days, whichmightmainly reﬂect
the in-uterometabolic changes.We thereafter investigated differences in
metabolite levels for an estimated breastfeeding length of 0 days in the n-
3 LCPUFA vs. placebo group and compared that to the same difference at
time of sampling; i.e. 6 months. These results are depicted in Fig. 3, and
the estimated 0 days of breastfeeding results only showed a signiﬁcant
difference for sphingomyelin (C37n1) and (C33n1), palmitoyl-
arachidonoyl-glycerol, hydroxy-CMPF, N-behenoyl-sphingadienine, and
3-(4-hydroxyphenyl) lactate between n-3 LCPUFA and placebo. All
these differences, except for hydroxy-CMPF, were no longer present at
6 months of age, suggesting that what we observe is mainly mediated
by the breastfeeding. However, these results should be interpreted with
caution, due to the uncertainty of the estimation.3.7. High-dose vitamin D intervention and child metabolomics at age
6 months
As 623 of the pregnant women in the n-3 LCPUFA trial also partici-
pated in high-dose vs. standard dose vitamin D supplementation DB-
RCT with a nested 2 × 2 factorial design, we also investigated whether
the vitamin D supplementation affected the child's metabolite levels
at age 6 months. No effect of the vitamin D supplementation was
observed on the child's metabolites levels using univariate linear
modelling (Figure SF8 in the Supplementary Material).
3.8. The n-3 LCPUFA metabolome and risk of asthma at age 5
We have previously demonstrated a 30.7% relative reduction in the
risk of developing asthma in the ﬁrst 5 years of life in children, whose
mothers were supplemented with n-3 LCPUFA during pregnancy com-
pared to placebo [3]. As we hypothesized that part of this risk reduction
could bemediated via the child metabolome, we tested possible associ-
ations between the components of the PLS-DAmodel and asthmadevel-
opment by age 5.
We initially found a signiﬁcant association between the second la-
tent score (sLV2) of the PLS-DAmodel and risk of asthmausing a Cox re-
gression analysis: hazard ratio (HR) per std. sLV2 increase: 0.80, 95% CI
0.65–1.26, p = .02 [Wald test]. In order to better disentangle the n-3
LCPUFA supplementation effect from the asthma association,we rotated
the PLS-DA model to capture the asthma mediated direction in the ﬁrst
component, leaving the supplementation effect in component two to
ﬁve. In Fig. 4, a Kaplan-Meier curve shows the risk of developing asthma
in theﬁrst 5 years of life in childrenwith LV1 score from the rotated PLS-
DA model (rsLV1) divided into tertiles. The curve shows that children
with a low rsLV1 n-3 LCPUFA-likemetabolome score, i.e. a metabolome
which is opposite to the n-3 LCPUFA metabolome, have an increased
risk of developing asthma irrespective of supplementation group: HR
0.76, (0.64–0.90), p= .002 [Wald test], with a change of one standard
deviation, i.e. lower risk from increasing n-3 LCPUFA-like metabolome.
Stratifying the analysis by the n-3 LCPUFA supplementation, we ob-
served a signiﬁcant association in the placebo strata but not in the n-3
Fig. 2. Results from the enrichment analysis using Fisher's exact test. The odds ratio from each sub-pathway and the corresponding CI at 95% are colored based on the−log10(p-value),
whereas the size of the colored circles is based on the number of compounds (from the PLS-DA) in the corresponding sub-pathway. (*): p.value b .05.
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mentation on the metabolome in the n-3 LCPUFA group: per std. rsLV1,
HRplacebo 0.65, (0.50–0.85), p = .002 [Wald test] and HRLCPUFA 0.89,
(0.69–1.15), p= .38 [Wald test], respectively, see Fig. 5.
Aswe observed inﬂuence on the childmetabolome fromboth FADS2
genotype and breastfeeding length,we adjusted themodel for these pa-
rameters. From such sensitivity analysiswedid not observe dependency
from either exclusive breastfeeding duration or FADS2 genotype on the
relationship between rLV1 and asthma risk: adjusted HR 0.75
(0.63–0.91), p= .003 [Wald test]. Furthermore, we also tested whether
adjustments either for current breastfeeding at the time of sampling
and total breastfeeding duration would inﬂuence the association with
asthma development, but no inﬂuence was found.
Finally, we investigated whether the asthma-protective effect from
the n-3 LCPUFA supplementation during pregnancy was mediated via
the metabolome by using rLV1 as a proxy of the n-3 LCPUFA-
associatedmetabolome by age 6months. The result from thismediation
analysis showed that 24% of the asthma-protective effect is mediated
through the metabolome (see Table S4).
4. Discussion
4.1. n-3 LCPUFA supplementation during pregnancy and the child
metabolome
We observed a decrease in metabolite levels linked to the n-6 path-
way in children, whose mothers received ﬁsh oil during pregnancy. It
has previously been observed that a dietary increased intake of 20:5n-
3 eicosapentaenoic acid (n3-EPA) and 22:6n-3 docosahexaenoic acid(n3-DHA) leads to a decrease of arachidonic acid (20:4n-6, AA) biosyn-
thesis due to inhibition of Δ6 desaturation of linoleic acid (18:2n-6)
[17,18]. In line with this, we observed decreased levels of AA in the n-
3 LCPUFA supplementation group along with a reduction in levels of
the AA precursor dihomo-linolenic acid (20:3n-6). We also registered
lower levels of AA esteriﬁed glycerophospholipids, possibly due to acyl-
ation afﬁnity for AA compared to the subsequent products in the path-
way, which also undergo peroxisomal beta-oxidation, partially leading
back to AA [19]. Finally, we observed decreased levels in the n-3
LCPUFA group of the end product in the n-6 pathway, docosapentaenoic
acid (22:5n-6), which is probably due to a lack of AA as substrate aswell
as for the plasmalogens and diacylglycerols containing AA in the sn-2
position. Overall, it might be speculated that the n-3 LCPUFA supple-
mentation led to some of the AA being replaced by EPA or DHA in the
structural lipids; however, in our untargeted metabolomics analysis
we did not observe an increase in the n-3 LCPUFAs or in their
phospholipids.
With regard to lipids, we observed that the n-3 LCPUFA supplemen-
tation induced changes in the child metabolome with a decrease in
levels of ceramides and sphingolipids containing 18:0 and 22:0 FAs. It
can be speculated that there is an inﬂuence in the fatty acid metabolism
from the stearic acid (18:0) to docosanoic acid (22:0) formation and a
successive decrease in phospholipid formation.
The n-3 LCPUFA supplementation led to decreased levels of
xanthurenic acid, which is a catabolic product from tryptophan in the
kynurenine pathway. Xanthurenic acid is produced by the transamina-
tion of 3-hydroxykynurenine, a compound that can generate free radi-
cals and apoptosis [20]. The indoleamine 2,3-dioxygenase 1 and 2
(IDO1/IDO2) enzymes are the main rate limiting enzymes activating
Table 2
Associations between FADS2 polymorphism (rs1535) and child n-6 pathway-related metabolite levels stratiﬁed by the intervention (n-3 LCPUFA supplement or placebo). Reported p-
values are from “Wald test”.
Metabolite, Sub-pathway Intervention Mother's genotype Child's genotype
beta-Estimate p.value CI beta-Estimate p.value CI
1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)*, Plasmalogen Placebo −0.29 0.01 −0.51 -0.08 0.07 0.52 −0.15 0.29
1-(1-Enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)*, Plasmalogen LCPUFA −0.10 0.32 −0.3 0.1 0.01 0.93 −0.2 0.22
1-(1-Enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)*, Plasmalogen Placebo −0.34 b0.001 −0.51 -0.18 0.09 0.29 −0.08 0.27
1-(1-Enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)*, Plasmalogen LCPUFA −0.06 0.53 −0.25 0.13 −0.01 0.90 −0.21 0.19
1-Arachidonoyl-GPC (20:4n6)*, Lysophospholipid Placebo −0.24 0.02 −0.45 -0.04 −0.05 0.66 −0.26 0.17
1-Arachidonoyl-GPC (20:4n6)*, Lysophospholipid LCPUFA −0.13 0.16 −0.32 0.05 −0.12 0.24 −0.32 0.08
1-Arachidonoyl-GPE (20:4n6)*, Lysophospholipid Placebo −0.19 0.07 −0.4 0.02 0.17 0.12 −0.05 0.39
1-Arachidonoyl-GPE (20:4n6)*, Lysophospholipid LCPUFA −0.17 0.09 −0.36 0.03 −0.01 0.95 −0.21 0.2
1-Palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6), Phosphatidylcholine (PC) Placebo −0.43 b0.001 −0.62 -0.24 0.08 0.45 −0.12 0.28
1-Palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6), Phosphatidylcholine (PC) LCPUFA −0.05 0.61 −0.25 0.15 −0.22 0.04 −0.43 -0.01
1-Stearoyl-2-arachidonoyl-GPC (18:0/20:4), Phosphatidylcholine (PC) Placebo −0.34 b0.001 −0.53 -0.15 0.00 0.97 −0.19 0.2
1-Stearoyl-2-arachidonoyl-GPC (18:0/20:4), Phosphatidylcholine (PC) LCPUFA −0.05 0.61 −0.25 0.15 −0.17 0.12 −0.39 0.04
1-Stearoyl-2-arachidonoyl-GPI (18:0/20:4), Phosphatidylinositol (PI) Placebo −0.23 0.03 −0.45 -0.02 0.09 0.40 −0.13 0.32
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4), Phosphatidylinositol (PI) LCPUFA −0.13 0.22 −0.33 0.08 −0.05 0.67 −0.26 0.17
Arachidonate (20:4n6), Polyunsaturated Fatty Acid (n3 and n6) Placebo −0.17 0.11 −0.39 0.04 0.07 0.54 −0.15 0.29
Arachidonate (20:4n6), Polyunsaturated Fatty Acid (n3 and n6) LCPUFA −0.09 0.35 −0.28 0.1 0.02 0.84 −0.18 0.22
Dihomo-linolenate (20:3n3 or n6), Polyunsaturated Fatty Acid (n3 and n6) Placebo −0.17 0.10 −0.37 0.03 0.17 0.11 −0.04 0.38
Dihomo-linolenate (20:3n3 or n6), Polyunsaturated Fatty Acid (n3 and n6) LCPUFA −0.07 0.49 −0.25 0.12 0.15 0.14 −0.05 0.35
Docosapentaenoate (n6 DPA; 22:5n6), Polyunsaturated Fatty Acid (n3 and n6) Placebo −0.24 0.04 −0.46 -0.01 0.22 0.07 −0.02 0.45
Docosapentaenoate (n6 DPA; 22:5n6), Polyunsaturated Fatty Acid (n3 and n6) LCPUFA −0.01 0.87 −0.19 0.16 −0.01 0.96 −0.2 0.18
Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2]*, Diacylglycerol Placebo −0.30 0.01 −0.52 -0.08 0.19 0.10 −0.04 0.42
Palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2]*, Diacylglycerol LCPUFA −0.13 0.11 −0.3 0.03 0.03 0.77 −0.15 0.2
Stearidonate (18:4n3), Polyunsaturated Fatty Acid (n3 and n6) Placebo −0.09 0.48 −0.33 0.16 0.03 0.84 −0.23 0.28
Stearidonate (18:4n3), Polyunsaturated Fatty Acid (n3 and n6) LCPUFA −0.02 0.81 −0.18 0.14 −0.05 0.54 −0.22 0.12
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1]*, Diacylglycerol Placebo −0.30 0.01 −0.51 -0.09 −0.10 0.36 −0.32 0.12
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [1]*, Diacylglycerol LCPUFA −0.21 0.02 −0.39 -0.04 −0.16 0.09 −0.34 0.02
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [2]*, Diacylglycerol Placebo −0.31 b0.001 −0.52 -0.09 −0.08 0.50 −0.3 0.15
Stearoyl-arachidonoyl-glycerol (18:0/20:4) [2]*, Diacylglycerol LCPUFA −0.17 0.06 −0.35 0.01 −0.04 0.70 −0.23 0.16
beta-Estimates are per copy of the G minor allele in rs1535. All the metabolites were autoscaled prior to the analysis.
Fig. 3. Difference between metabolite levels in the n-3 LCPUFA and placebo group at estimated age 0 (estimated from the intercept) and at age 6 months. Bars show the difference in the
beta-estimates and they are color coded based on the p-values. The metabolites were autoscaled prior analysis. Reported p-values are from “Wald test” (*): p-value b .05.
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408 D. Rago et al. / EBioMedicine 46 (2019) 399–410tryptophan catabolism through the kynurenine pathway. IDO expres-
sion is induced by lipopolysaccharides and cytokines, especially by in-
terferon gamma (IFN-y), that acts on T-cells and promotes
differentiation and apoptosis via the T-cell receptor [21]. Our ﬁndings
suggest that n-3 LCPUFA supplementation has an impact on the regula-
tion of IDO expression, that may be caused by anti-inﬂammatory activ-
ity and reduced IFN-y levels, leading to a reduction in tryptophan
catabolism in the kynurenine pathway.
Medium- and short-chain acyl-carnitine were also affected with
lower levels in the n-3 LCPUFA group. Acyl-carnitines are reversibly
formed by the reaction of the acyl-CoA esters with carnitine, a process
catalyzed by carnitine acyl-transferase. This mechanism takes place to
transport the FAs with N14 carbons into the mitochondrial membrane
for their subsequent beta-oxidation [22]. The concentration of
acyl-carnitines in plasma also reﬂects the nutritional state and the
contribution from other tissues, in particular, medium and long-chain
acyl-carnitine are directly derived from the fatty acid metabolism. It
can be speculated that n-3 LCPUFA supplementation may inﬂuence
the beta-oxidation in the mitochondria, probably increasing the beta-
oxidation, and therefore limiting the accumulation of intermediate
lipid products. We also observed an increase in carnitine biosynthesis,
with both carnitine and its precursor trimethyllysine being enhanced
in the n-3 LCPUFA group.
In the n-3 LCPUFA group, we also observed an increase in tyrosine
catabolism and its derived catecholamines breakdown products. Specif-
ically, we observed an increase in vanillylmandelic acid, the main inac-
tive catabolic product of norepinephrine and epinephrine. These
catecholamines are produced from dopamine and act as hormones
and neurotransmitters and are synthesized in the brain and in the adre-
nal gland. The other upregulated compounds in this pathway, 3-(4-
hydroxyphenyl)lactate and 3-methoxytyramine sulfate, aremetabolites
originating from dopamine catabolism. It has been shown that rats
chronically deﬁcient in n-3 FAs have effects on the monoaminergic sys-
tem during development with different effect in different regions of the
cortex [23]. Furthermore, rats receiving a n-3 LCPUFA-enriched diet that
was poor in linoleic acid (18:2n-6) [24] showed signiﬁcant differences
in the FA composition in the cerebral membranes with higher levels of
docosahexaenoic acid (22:6n-3), that is the most abundant n-3 FA inFig. 4. Kaplan-Meier curve of the ﬁrst component of the rotated PLS-DA modethe brain, lower levels of AA and higher levels of dopamine. It has also
been shown in mice that ﬁsh oil supplementation upregulates the ex-
pression of the mitochondrial uncoupling protein 1 in the brown and
beige adipose tissue, which affects fat accumulation. The brown adipose
tissue activity is primarily regulated by the sympathetic nervous
system, which releases norepinephrine that successively binds the
beta-adrenergic receptors and promotes the expression. This aligns
with observations of increased release of norepinephrine in the urine
of mice receiving ﬁsh oil supplementation [25] and may partly explain
the relationship between the n-3 LCPUFA supplementation and upregu-
lation of the tyrosine pathway.
The n-3 LCPUFA supplementation was also associated with an
increase in glutamate, 4-hydroxy-glutamate, which is a byproduct
of 4-hydroxy-2-oxoglutarate, and alpha-ketoglutarate which is a
deamination product and precursor of glutamate. Glutamate is a non-
essential amino acid that can be synthetized from alpha-ketoglutarate,
glutamine and pyroglutamic acid. Glutamate is involved in several path-
ways both as substrate and product and is also an excitatoryneurotrans-
mitter [26]. So far, no direct associations have been found between n-3
LCPUFA intake and the glutamate metabolism.
Hydroxy-CMPF and 3-carboxy-4-methyl-5-pentyl-2-
furanpropanoic acid are metabolites, which in humans come from
beta-oxidation and omega-oxidation of furan FAs. Furan FAs are formed
in plants, bacteria, and algae and they accumulate in the tissues of ﬁsh
and crustaceans [27]. In humans, the uptake of the furan FAs is through
food such as vegetables and vegetable oils, ﬁsh and ﬁsh oil. However,
there is a hypothesis of de novo synthesis of CMPF by the gutmicrobiota
[27].Weobserved amuch higher level of hydroxy-CMPF in the children,
whose mothers received ﬁsh oil-derived n-3 LCPUFA compared to
placebo, which is presumably directly related to the ﬁsh oil supplemen-
tation and therefore serves as a biological validation of the metabolo-
mics dataset.
4.2. FADS2 genotype and n-3 LCPUFA supplementation
The amount of n-3/n-6 LCPUFA is dependent on food or supplemen-
tation but also on the activity of the Δ5- and Δ6-desaturase enzymes,
which converts the essential FAs into LCPUFAs. The mother's FADS2l (rLV1) divided into tertiles and the risk of developing asthma by age 5.
Fig. 5. Kaplan-Meier curve of the ﬁrst component of the rotated PLS-DA model (rLV1) divided into tertiles and the risk of developing asthma by age 5, stratiﬁed by intervention.
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pathway whereas the child's genotype was not. It might be that the
child's metabolite levels in this pathway are primarily a reﬂection of
the maternal levels via breastfeeding [28]. Furthermore, the quasi sig-
niﬁcant association of the main FAs is in line with previous studies
showing that the minor allele is associated with lower enzyme activity
and therefore lower levels of fatty acid products [28,29], in our case
AA, n-6 DPA and 20:3n6. The reason why we observe a stronger signif-
icance for the AA derived products could be due to a better sensitivity
for the compounds further down the cascade process, but still directly
derived from AA. The effect of the genotype is predominant in the pla-
cebo strata compared to the ﬁsh oil strata, probably due to the effect
of the supplementation, which affects the activity of the desaturase en-
zyme and probably masking and compensating for the genotype effect.
4.3. Breastfeeding effect on the child metabolome
Weobserved a strong inﬂuence of breastfeeding duration onmetab-
olites in both the n-3 LCPUFA and placebo strata and used this informa-
tion to address whether the n-3 LCPUFA supplementation induced a
pre- or post-natal programming effect on the childmetabolome. Our re-
sults suggest that the n-3 LCPUFA supplementation effects on the child's
metabolome are mainly originating from the composition of the
mother's breast milk. However, most of the differences in metabolite
levels between n-3 LCPUFA and placebo for estimated 6 months and
0 days of breastfeeding have the same directionality and theﬁt of the re-
gressionmodelmay suffer from fewer cases of children not being exclu-
sively breastfed for a long period of time, thus effecting the estimation at
0 days. We assume that breastfeeding duration plays an important role
in enhancing the level of n-3 LCPUFAs in the children, but at the same
time, we speculate that some of the compounds seem to be transferred
through the placenta or are altered due to prenatal changes, even
though we need metabolomics proﬁles of the children's plasma at
birth to verify this assumption. Further, assessments of maternal meta-
bolomics proﬁles would enable us to disentangle whether the n-3
LCPUFA supplementation during pregnancy lead to sustained changes
in mother's metabolite levels, which could be transferred to the childvia the breastmilk. If it is correct that most of the metabolite differences
in relation to n-3 LCPUFA supplementation are a result of breastfeeding,
it suggests that breastfeedingmay accentuate the effects of prenatal n-3
LCPUFA supplementation.
4.4. n-3 LCPUFA-associated metabolome and asthma-protective effect
We aimed to relate the effect of the n-3 LCPUFA supplementation on
the child metabolome to the observed asthma-protective effect in our
DB-RCT to disentangle the underlying biochemical mechanisms. Our
analysis suggested that the n-3 LCPUFA supplementation associated
metabolome mediated 24% of the asthma-protective effect.
Part of the mediation effect on asthma may be explained by the
down-regulation of the n-6 LCPUFAs and their esteriﬁed compounds.
Particularly, AA is one of the most abundant LCPUFAs in the cells in-
volved in the inﬂammatory process leading to asthma symptoms. AA
is a substrate for cyclooxygenase, lipoxygenase and cytochrome P450
enzymes to produce eicosanoids, which are potent mediators of airway
inﬂammation. Thus, the prostaglandins 2-series (PGE2) are involved in
the induction of the proinﬂammatory interleukin 6 (IL-6) [30] and in-
creased levels of the leukotrienes LTC4 and LTD4 resulting in
bronchoconstriction, increasedmucus secretion, and airway hyperreac-
tivity, that leads to airﬂow obstruction in asthma patients [31]. In line
with this, a case-control study among adults with asthma have previ-
ously shown increased circulating AA levels [32].
We also observed an association of the n-3 LCPUFA supplementation
on the glutamate pathway. Glutamate is involved in several pathways,
including the gamma-glutamyl cycle in the liver, where glutathione is
produced from glutamate cysteine and glycine [33]. Glutathione is an
antioxidant compound and lower levels of glutamic acid, glycine and ty-
rosine have previously been demonstrated in asthmatic children [34],
thus connecting childhood asthma with a decreased antioxidant de-
fense. In our study, we observed that children, whose mother received
n-3 LCPUFA had higher levels of tyrosine, glutamic acid as well as
dimethylglycine and sarcosine, which are precursors of glycine, thereby
linking the n-3 LCPUFA supplementation to an improved antioxidant
system, which may have played an asthma-protective role.In this
410 D. Rago et al. / EBioMedicine 46 (2019) 399–410study we demonstrate that n-3 LCPUFA supplementation with ﬁsh oil
during pregnancy signiﬁcantly associates with the offspring metabo-
lome by age 6 months. The observed effects were primarily a decrease
in metabolites in the n-6 LCPUFA and tryptophan pathways, as well as
an increase in the tyrosine and glutamate pathways. We further show
that the ﬁsh oil metabolomic proﬁle was associated with a reduced
risk of asthma by age 5 and that these biochemical alterationsmediated
one fourth of the asthma-protective effect of the supplementation.
These ﬁndings provide new important insight into the effects of dietary
n-3 LCPUFA supplementation and the pathogenesis of childhood
asthma.
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